EA200701246A1 - Стабильные при комнатной температуре составы дронабинола - Google Patents

Стабильные при комнатной температуре составы дронабинола

Info

Publication number
EA200701246A1
EA200701246A1 EA200701246A EA200701246A EA200701246A1 EA 200701246 A1 EA200701246 A1 EA 200701246A1 EA 200701246 A EA200701246 A EA 200701246A EA 200701246 A EA200701246 A EA 200701246A EA 200701246 A1 EA200701246 A1 EA 200701246A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dronabinol
room temperature
under room
stable under
temperature compositions
Prior art date
Application number
EA200701246A
Other languages
English (en)
Inventor
Джордж С. Коттейил
Чжунюань Чжу
Венкат Р. Госконда
Original Assignee
Инсис Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инсис Терапьютикс, Инк. filed Critical Инсис Терапьютикс, Инк.
Publication of EA200701246A1 publication Critical patent/EA200701246A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложен стабильный при комнатной температуре состав каннабиноида. В предпочтительных вариантах воплощения составом каннабиноида является дронабинол в носителе на основе масла, заключенный в твердую желатиновую капсулу.
EA200701246A 2004-12-09 2005-12-09 Стабильные при комнатной температуре составы дронабинола EA200701246A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63447404P 2004-12-09 2004-12-09
PCT/US2005/044375 WO2006063109A2 (en) 2004-12-09 2005-12-09 Room-temperature stable dronabinol formulations

Publications (1)

Publication Number Publication Date
EA200701246A1 true EA200701246A1 (ru) 2008-06-30

Family

ID=36578552

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701246A EA200701246A1 (ru) 2004-12-09 2005-12-09 Стабильные при комнатной температуре составы дронабинола

Country Status (12)

Country Link
US (1) US8628796B2 (ru)
EP (1) EP1827393A4 (ru)
JP (1) JP5153341B2 (ru)
KR (1) KR20070118069A (ru)
CN (1) CN101132781A (ru)
AU (1) AU2005314021B2 (ru)
CA (1) CA2589993C (ru)
EA (1) EA200701246A1 (ru)
IL (2) IL183815A0 (ru)
MX (1) MX2007007038A (ru)
NZ (1) NZ555701A (ru)
WO (1) WO2006063109A2 (ru)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316832A (zh) 2005-09-29 2008-12-03 Amr科技公司 δ-9-四氢大麻酚的生成方法
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
AU2016203127B2 (en) * 2005-11-07 2018-07-12 Murty Pharmaceuticals, Inc An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
US8039509B2 (en) * 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
CA2698752A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
KR101096429B1 (ko) * 2008-07-18 2011-12-20 한국유나이티드제약 주식회사 안정성이 향상된 아세클로페낙의 경구용 연질캅셀제
US8735374B2 (en) * 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
MX2012005264A (es) * 2009-11-09 2012-07-03 Capsugel Belgium Nv Portador de suministro.
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20120043242A1 (en) * 2010-08-19 2012-02-23 Andrew David Hospodor Medicinal cannabis fatty foodstuff
GB201019525D0 (en) * 2010-11-18 2010-12-29 Shire Llc Oil-based formulations
WO2012071389A2 (en) 2010-11-22 2012-05-31 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8741341B2 (en) * 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
WO2014030053A1 (en) * 2012-08-20 2014-02-27 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
CN103110582A (zh) * 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2015065180A1 (en) 2013-10-29 2015-05-07 Echo Pharmaceuticals B.V. Compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
EP3001812B1 (en) 2013-10-29 2016-11-02 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
US9259449B2 (en) 2014-01-07 2016-02-16 Joshua Michael Raderman Method for modifying THC content in a lipid-based extract of cannabis
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
AU2015238301B2 (en) 2014-03-26 2020-06-25 Astex Therapeutics Ltd Combinations
EP4151234A1 (en) * 2014-05-29 2023-03-22 Fresh Cut Development, LLC Stable cannabinoid formulations
US20170224634A1 (en) * 2014-05-29 2017-08-10 Insys Development Company, Inc. Stable cannabinoid formulations
US11911361B2 (en) * 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US20160367496A1 (en) * 2014-05-29 2016-12-22 Insys Development Company, Inc. Stable cannabinoid formulations
US20160271252A1 (en) * 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
US11331279B2 (en) * 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
WO2015195990A1 (en) * 2014-06-20 2015-12-23 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
WO2016105514A1 (en) * 2014-12-23 2016-06-30 Biotech Institute, Llc A reliable and robust method for the analysis of cannabinoids and terpenes in cannabis
CA3012599A1 (en) 2015-01-26 2016-08-04 Matthew W. Giese Systems, apparatuses, and methods for classification
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016144376A1 (en) * 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
EP3270896A4 (en) * 2015-03-19 2018-09-12 One World Cannabis Ltd. Preparations of cannabis emulsions and methods thereof
ES2938560T3 (es) * 2015-05-28 2023-04-12 Radius Pharmaceuticals Inc Formulaciones de cannabinoides estables
US20170143664A1 (en) * 2015-08-06 2017-05-25 Charles E. Ankner Cannabinoid formulation for the sedation and/or anaesthetizing of a human or animal
CA3003094A1 (en) 2015-10-31 2017-05-04 Aharon M. Eyal Honey-cannabinoid therapeutic composition
US11590230B2 (en) * 2015-12-07 2023-02-28 Elka Touitou Compositions of therapeutic substances, methods and uses thereof
US20180117161A1 (en) * 2015-12-09 2018-05-03 Poviva Tea, Llc Methods for formulating orally ingestible compositions comprising lipophilic active agents
CA3010861A1 (en) * 2016-01-08 2017-07-13 Colonaryconcepts Llc Food based delivery of cannabinoids
WO2017137992A1 (en) * 2016-02-11 2017-08-17 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
WO2017208072A2 (en) * 2016-06-02 2017-12-07 Acerus Pharmaceutical Corporation Nasal cannabidiol compositions
WO2017218853A1 (en) * 2016-06-15 2017-12-21 Ojai Energetics Pbc Methods and compositions for reducing oxidative stress
KR20190034576A (ko) 2016-08-03 2019-04-02 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US10624872B1 (en) * 2017-06-29 2020-04-21 Charlotte's Web, Inc. Apparatuses, methods, and systems for extraction, isolation and conversion of various cannabinoids, and modifications of whole-plant hemp extracts therewith
US10307392B2 (en) 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
US10722545B2 (en) 2018-01-01 2020-07-28 Alexander Kariman Compound and method for treatment of movement disorders
US20190209517A1 (en) * 2018-01-10 2019-07-11 Insys Development Company, Inc. Methods of stabilizing dronabinol
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
EP3773466A4 (en) * 2018-04-13 2022-03-09 Omeza LLC TOPICAL COMPOSITION COMPRISING COD LIVER OIL FOR THE TREATMENT OF WOUNDS AND SKIN DISORDERS
WO2019217793A1 (en) * 2018-05-11 2019-11-14 Rhodes Technologies Inc. Compositions and dosage forms for oral delivery
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
WO2021046189A1 (en) * 2019-09-06 2021-03-11 Quicksilver Scientific, Inc. Microemulsion delivery systems for water-based beverages
US11497249B2 (en) 2019-09-16 2022-11-15 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
US20210213083A1 (en) * 2020-01-15 2021-07-15 Resurgent Biosciences, Inc. Water soluble cannabinoid powders
WO2021163023A1 (en) * 2020-02-10 2021-08-19 TRYAGx Labs Inc. Stable formulations of dronabinol
MX2022013090A (es) 2020-04-20 2022-11-14 Poviva Corp Composiciones y metodos para el suministro mejorado de agentes antivirales.
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
WO2024026200A1 (en) * 2022-07-27 2024-02-01 Redox Bioscience LLC Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
WO2024088844A1 (de) * 2022-10-25 2024-05-02 Stoermer Talleur Bernd Cannabinoidlösung in öl

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668224A (en) 1970-07-02 1972-06-06 Theodor Petrzilka PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS
EP0266443B1 (en) 1986-11-03 1993-06-23 Allen W. Jacobs Process for the inclusion of a solid particulate component into aerosol formulations of inhalable nicotine
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
DE3305755A1 (de) 1983-02-19 1984-08-23 Gödecke AG, 1000 Berlin N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
EP0656779B1 (en) 1992-08-28 2000-04-12 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5360648A (en) 1993-06-24 1994-11-01 The Dow Chemical Company Pouch for packaging flowable materials
US5430021A (en) 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5447729A (en) 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
DE19706903A1 (de) 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
US5804592A (en) * 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
AU766988B2 (en) 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
US6008383A (en) 1998-10-26 1999-12-28 University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol esters
US6730519B2 (en) 1998-10-26 2004-05-04 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
US6365416B1 (en) 1998-10-26 2002-04-02 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US6711122B1 (en) * 1999-02-08 2004-03-23 Radiolan, Inc. Frequency offset differential pulse position modulation
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
EP1109533A1 (en) 1999-07-08 2001-06-27 Orlando Hung Pulmonary delivery of liposome-encapsulated cannabinoids
US7648696B2 (en) 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
US6747058B1 (en) 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
PT1280515E (pt) 2000-03-09 2007-04-30 Gw Pharma Ltd Compisoções farmacêuticas que compreendem canábis
US6623765B1 (en) 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
AU2002231970B2 (en) 2001-02-14 2007-08-16 GW Research Limited Mucoadhesive pharmaceutical formulations
GB2381194A (en) * 2001-09-07 2003-04-30 Gw Pharmaceuticals Ltd Pharmaceutical formulations
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US7399872B2 (en) 2001-03-07 2008-07-15 Webster G R Barrie Conversion of CBD to Δ8-THC and Δ9-THC
US6503532B1 (en) 2001-04-13 2003-01-07 Murty Pharmaceuticals, Inc. Pharmaceutical composition containing tetrahydrocannabinol and a transdermal/transcutaneous delivery method thereof
GB2377218A (en) 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
GB0112752D0 (en) 2001-05-25 2001-07-18 Johnson Matthey Plc Synthesis of cannabinoids
TW200407110A (en) 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
NZ534430A (en) 2002-02-01 2007-09-28 Resolution Chemicals Ltd Production of delta 9 tetrahydrocannabinol from plant material
UA79281C2 (en) * 2002-04-03 2007-06-11 Solvay Pharm Bv Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US7344736B2 (en) 2002-08-14 2008-03-18 Gw Pharma Limited Extraction of pharmaceutically active components from plant materials
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
PT1560819E (pt) 2002-11-12 2008-11-03 Mallinckrodt Inc Derivados cristalinos dos canabinóides e processo de purificação dos canabinóides
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20040229939A1 (en) 2003-02-14 2004-11-18 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
WO2005044093A2 (en) 2003-11-05 2005-05-19 Unimed Pharmaceuticals, Inc. Delta-9- the treatment of multiple sclerosis
CA2552925A1 (en) 2004-01-30 2005-08-18 Pfizer Italia S.R.L. Semisolid matrix pharmaceutical formulations
US7323576B2 (en) 2004-10-01 2008-01-29 Alphora Research Inc. Synthetic route to dronabinol
WO2006091922A1 (en) 2005-02-25 2006-08-31 Unimed Pharmaceuticals, Inc. Dronabinol compositions and methods of using same
US20060258738A1 (en) 2005-05-12 2006-11-16 Douglas Dieterich Use of dronabinol for treatment of side effects of Hepatitis C therapy
AU2006247526A1 (en) 2005-05-13 2006-11-23 Unimed Pharmaceuticals, Inc. Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
US7321047B2 (en) 2005-05-19 2008-01-22 Alphora Research Inc. Separation of tetrahydrocannabinols
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
RU2008101363A (ru) 2005-06-20 2009-07-27 Юнимед Фармасьютикалз, Инк. (Us) Лечение мигрений дронабинолом
US20070060639A1 (en) 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
WO2007056242A1 (en) 2005-11-07 2007-05-18 Murty Pharmaceuticals, Inc. Improved delivery of tetrahydrocannabinol

Also Published As

Publication number Publication date
JP5153341B2 (ja) 2013-02-27
EP1827393A4 (en) 2012-04-18
CA2589993C (en) 2012-07-03
MX2007007038A (es) 2008-03-07
US8628796B2 (en) 2014-01-14
WO2006063109A9 (en) 2006-07-20
CA2589993A1 (en) 2006-06-15
KR20070118069A (ko) 2007-12-13
US20060160888A1 (en) 2006-07-20
JP2008523078A (ja) 2008-07-03
WO2006063109A2 (en) 2006-06-15
WO2006063109A3 (en) 2007-02-22
AU2005314021B2 (en) 2010-02-11
IL205892A0 (en) 2010-11-30
CN101132781A (zh) 2008-02-27
AU2005314021A1 (en) 2006-06-15
EP1827393A2 (en) 2007-09-05
IL183815A0 (en) 2007-09-20
NZ555701A (en) 2011-05-27

Similar Documents

Publication Publication Date Title
EA200701246A1 (ru) Стабильные при комнатной температуре составы дронабинола
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
PA8621501A1 (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos
NO20091976L (no) Nye forbindelser
ATE359260T1 (de) Substituierte cyclohexan-1,4-diaminderivate
DK1644348T3 (da) Epoxy-afsluttede polythioethere, Epoxy-afsluttede polythioethere
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
BR0215405A (pt) Composições e processos de uso de collajolie
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
ATE412649T1 (de) Substituierte heteroarylbenzofuransäuren
RS51694B (en) NEW PERINDOPRIL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THERE
DK1536783T3 (da) Faste formuleringer, der omfatter en indolinonforbindelse
ATE478125T1 (de) Reversible thermochromische zusammensetzungen
ATE490273T1 (de) Gelatinkapseln
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
EA200300988A1 (ru) Производные фенил-гетероциклильных эфиров в качестве ингибиторов обратного захвата серотонина
SE9903290D0 (sv) Novel compounds
RS20060206A (en) Aminopyridine-derivatives as inducible no-synthase inhibitors
ATE403660T1 (de) Benzo 4,5 thieno 3,2-b pyran-2-on enthaltende duftstoffzusammensetzungen
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
ITTO20030879A1 (it) Composizione insetticida microincapsulata.
ATE398617T1 (de) Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase
ATE451366T1 (de) Sulphonamid benzoxazinonderivate. ihre herstellung und verwendung als medikamente